NCT04477343
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentUniversity of RochesterInvestigator-initiated
~20 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:SX-682Nivolumab Injectable Product
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum tolerable dose [Safety and Tolerability]
Measured over through study completion, an average of 6 months
Conditions
NCT04477343
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Rochester
Rochester, New Yorkno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Daniel Mulkerin, MD · PRINCIPAL_INVESTIGATOR · University of Rochester Wilmot Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
5 x ULN for subjects with liver metastases Bilirubin ≤ 1.5 mg/dL sa≤ 3.0 mg/dL for subjects with Gilbert's disease INR or PT ≤ 1.5 x ULN unless receiving anticoagulation therapy aPTT or PTT ≤ 1.5 x ULN unless receiving anticoagulation therapy 7. Life expectancy of ≥ 12 weeks as judged by the treating physician. 8. Patient must consent for baseline and on treatment biopsies 9. Patients must have baseline pulse oximetry ≥ 90% on room air
What this trial measures
- Maximum tolerable dose [Safety and Tolerability]through study completion, an average of 6 months
Maximum tolerable dose is defined by less than or equal to 30% dose limiting toxicity (DLT) event rate within a given dose combination,